ClinicalTrials.gg

Program

Hydroxyurea

Also written as “Hydroxyurea (HU)”, “Hydroxycarbamide” and “Hydroxycarbamid”.

Its studies are mostly in HIV Infections · Anemia, Sickle Cell · Polycythemia Vera · Glioblastoma, led by 4 companies.

Furthest: phase 4, since Aug 4, 20159 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Norgine51 open or runningphase 4since Aug 4, 2015Aug 4, 2015Feb 2028phase 2 · NCT06578507
Novartis20 open or runningphase 4since May 2, 2023Feb 10, 2006none ahead
Nova Laboratories10 open or runningphase 2since Dec 3, 2018Dec 3, 2018none ahead
Triangle Pharmaceuticals10 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: simbec-orion-group, oncodesign-sa, phinc-development, Pfizer and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 2 study in HIV InfectionsNew to Triangle PharmaceuticalsTriangle Pharmaceuticals · NCT00002412 · United States
  2. Feb 10, 2006Novartis's first study: phase 2 study in GlioblastomaNew to NovartisNovartis · NCT00290771 · 231 enrolled · United States
  3. Aug 4, 2015Norgine's first study: phase 4 study in Anemia, Sickle CellNew to NorgineNorgine · NCT02522104 · 40 enrolled · France
  4. Dec 3, 2018Nova Laboratories's first study: phase 2 study in Anemia, Sickle CellNew to Nova LaboratoriesNova Laboratories · NCT03763656 · 33 enrolled · Jamaica, United Kingdom
  5. Jan 9, 2019Phase 2 study in Anemia, Sickle CellNorgine · NCT03806452 · 86 enrolled · Côte D'Ivoire, France, Guadeloupe and more
  6. Aug 5, 2021Phase 1 study in Healthy VolunteersNorgine · NCT05025072 · 28 enrolled · United Kingdom
  7. Jul 19, 2022Phase 2 study in Anemia, Sickle CellNorgine · NCT05470270 · 33 enrolled · France
  8. May 2, 2023Phase 4 study in Polycythemia VeraNovartis · NCT05853458 · 76 enrolled · Germany
  9. Aug 22, 2024Phase 2 study in Anemia, Sickle CellNorgine · NCT06578507 · 50 planned · France, French Guiana
  10. Oct 1, 2026Primary completion moved from 2027-02 to 2028-02Date moved laterphase 2 · +12 months · NCT06578507

Ahead

  1. Feb 2028Primary completion: phase 2 study in Anemia, Sickle CellNorgine · NCT06578507

TargetBeta

“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
GemcitabineruleEli Lillyphase 4224

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06578507Anemia, Sickle Cell · France, French Guiana2RecruitingNorgineFeb 202850
NCT05853458Polycythemia Vera · Germany4TerminatedNovartisFeb 26, 202676
NCT05470270Anemia, Sickle Cell · France2CompletedNorgineOct 28, 202233
NCT05025072Healthy Volunteers · United Kingdom1CompletedNorgineSep 29, 202128
NCT03806452Anemia, Sickle Cell · Côte D'Ivoire, France, Guadeloupe and more2CompletedNorgineMay 30, 202486
NCT03763656Anemia, Sickle Cell · Jamaica, United Kingdom2CompletedNova LaboratoriesMay 19, 202133
NCT02522104Anemia, Sickle Cell · France4CompletedNorgineNov 201640
NCT00290771Glioblastoma · United States2TerminatedNovartisAug 2008231
NCT00002412HIV Infections · United States2CompletedTriangle Pharmaceuticals

How it is read

Names in the registry

  • “Hydroxyurea”, 7 entries
  • “Hydroxyurea (HU)”, 6 entries
  • “Hydroxycarbamide”, 2 entries
  • “Hydroxycarbamid”, 1 entry
  • “Hydroxycarbamide film-coated tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.